These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36067250)

  • 1. Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Zhu S; Ni Y; Wang Z; Zhang X; Zhang Y; Zhao F; Dai J; Wang Z; Zhu X; Chen J; Zhao J; Zeng Y; Chen N; Zeng P; Shen P; Sun G; Zeng H
    Oncologist; 2022 Nov; 27(11):e870-e877. PubMed ID: 36067250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
    Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone.
    Zhu S; Ni Y; Sun G; Wang Z; Chen J; Zhang X; Zhao J; Zhu X; Dai J; Liu Z; Liang J; Zhang H; Zhang Y; Shen P; Zeng H
    Cancer Med; 2021 Sep; 10(18):6282-6290. PubMed ID: 34318630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.
    Ni YC; Zhao JG; Zhang MN; Zhang YJ; Yang ZY; Chen N; Chen JR; Shen PF; Sun GX; Zhang XM; Li YH; Zeng H
    Asian J Androl; 2022; 24(2):154-160. PubMed ID: 34380864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
    Boerrigter E; Benoist GE; van Oort IM; Verhaegh GW; van Hooij O; Groen L; Smit F; Oving IM; de Mol P; Smilde TJ; Somford DM; Mehra N; Schalken JA; van Erp NP
    Mol Oncol; 2021 Sep; 15(9):2453-2465. PubMed ID: 33650292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo.
    Chen J; Yang Y; Xu D; Li J; Wu S; Jiang Y; Wang C; Yang Z; Zhao L
    Biochem Biophys Res Commun; 2021 Feb; 540():83-89. PubMed ID: 33450484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKR1C3-negative high-risk metastatic castration-sensitive prostate cancer has long-term response to first-line treatment with abiraterone: Four case reports.
    Yoshizawa T; Nakanishi Y; Obinata D; Yamaguchi K; Masuda S; Takahashi S
    Urol Case Rep; 2024 May; 54():102727. PubMed ID: 38617182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
    Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
    Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
    Hertzog JR; Zhang Z; Bignan G; Connolly PJ; Heindl JE; Janetopoulos CJ; Rupnow BA; McDevitt TM
    Prostate; 2020 Oct; 80(14):1223-1232. PubMed ID: 33258507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
    Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
    Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression.
    Wang B; Wu S; Fang Y; Sun G; He D; Hsieh JT; Wang X; Zeng H; Wu K
    J Cell Mol Med; 2020 Oct; 24(20):12032-12043. PubMed ID: 32902124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.
    Miyazaki Y; Teramoto Y; Shibuya S; Goto T; Okasho K; Mizuno K; Uegaki M; Yoshikawa T; Akamatsu S; Kobayashi T; Ogawa O; Inoue T
    J Clin Med; 2019 May; 8(5):. PubMed ID: 31052459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.
    Tian Y; Zhao L; Zhang H; Liu X; Zhao L; Zhao X; Li Y; Li J
    Diagn Pathol; 2014 Feb; 9():42. PubMed ID: 24571686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined
    Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
    Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
    Zhou M; Wang X; Xia J; Cheng Y; Xiao L; Bei Y; Tang J; Huang Y; Xiang Q; Huang S
    Int J Nanomedicine; 2020; 15():3087-3098. PubMed ID: 32431503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer.
    Hiew K; Hart CA; Ali A; Elliott T; Ramani V; Sangar V; Lau M; Maddineni S; Brown M; Clarke N
    Eur Urol Focus; 2019 Sep; 5(5):831-841. PubMed ID: 29699892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.